Vaccination of older people – not only SARS-CoV-2 vaccine

Česká verzia

Authors: Eva Topinková
Authors place of work: Geriatrická klinika 1. LF UK a VFN, Praha
Published in the journal: Geriatrie a Gerontologie 2021, 10, č. 3: 117-126
Category: Review Article

Summary

Immunization against infectious diseases belongs historically to the most successful medical preventive approaches. Currently, more than 20 vaccines against the most life-threatening infections are available. It is recommended to vaccinate not only children but also in adulthood and in older age. Seniors and other vulnerable groups of persons with chronic diseases benefit most from targeted vaccination strategies. Earlier this year WHO launched a strategy „Immunization Agenda 2030: A Global Strategy to Leave No One Behind“ and International Federation on Ageing started campaign „Vaccines4Life“ with the aim to support and improve awareness of public on vaccination and its importance for healthy ageing, to make vaccination an important societal priority and strengthen nation vaccination strategies. In addition to currently discussed and implemented vaccination against SARS-CoV-2 which is prioritized in the coronavirus pandemic struggle it is equally important to continue with other regular vaccinations. In older age the universally recommended is the influenza and pneumococcal diseases vaccination which are very effective in preventing the risk of infection, severity of the disease and infection-related functional decline/disability. Both vaccines are fully covered from health insurance and were found to have a long-term beneficial effect on overall mortality, cardiovascular events, and stroke. Further, Czech vaccinology society recommends vaccination against herpes zoster, tetanus, and pertussis. The article summarizes current information on recommended vaccines in person 65 years and over.

Keywords:

vaccination – older persons – missed opportunity to vaccinate – vaccination against pneumococcal and influenza infections – WHO Immu-nization Agenda 2030 – Vaccines4Life

Zdroje

Nnaji CA, Owoyemi AJ, Amaechi UA, et al. Taking stock of global immunisation coverage progress: the gains, the losses and the journey ahead. Int Health 2020 (published online Jan 11).
World Health Organization. Methodology for the assessment of missed opportunities for vaccination. Geneva 2017.
World Health Organization. Immunization Agenda 2030. Geneva 2021.
Immunization agenda 2030. A global strategy to leave no one behind. IA2030. www.immunizationagenda2030.org.
The Lancet 2021: The beginning of a new era of immunisations? Editorial. Lancet 2021; 397: 1519.
IFA’s ’60 Second Fact Check: Vaccine Safety for Older Adults’ campaign. Dostupné na: https://www.youtube.com.
Očkovací kalendář pro dospělé – podle věku. Česká vakcinologická společnost ČLS JEP 2019. Dostupné na: vakcinace.eu.
Maďar R. Chřipka – významná příčina morbidity a mortality populace. Remedia 2015; 25: 370–372.
Kynčl J. Chřipka v kontextu aktuálních opatření u koronaviru. SZÚ 2020. Dostupné na: czu.cz.
Kynčl J, Havlíčková M. Chřipka – opomíjené preventabilní onemocnění. Med praxi 2011; 8(9): 351–353.
Weinberger B (ed). Vaccines for Older Adults: Current Practices and Future Opportunities. Interdiscip Top Gerontol Geriatr. Basel: Karger 2020; 43: 98–112.
Jágrová Z. Chřipka. 14. Hradecké vakcinologické dny 2019.
McElhaney JE, et al. The immune response to influenza in older humans: beyond immune senescence. Immunity Ageing 2020; 17: 10.
Warren-Gash Ch, Blackburn R, Whitaker H, et al. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Resp J 2018; 51: 1701794.
Michel JP, Doherty TM, Pasquale D. Precision medicine and vaccination of older adults: from reactive to proactive (a mini review). 2020. Dostupné z: www.karger.com/Article/FullText/503141.
Michel JP. The well-known and less well-known benefits of vaccines. Aging Clin Exp Res 2020; 3: 1401–1404.
Fountoulaki K, Tsiodras S, Polyzogopoulou E, et al. Beneficial effects of vaccination on cardiovascular events: Myocardial infarction, stroke, heart failure. Cardiology 2018; 141(2): 98–106.
Modin D, Jørgensen ME, Gislason G, et al. Influenza Vaccine in Heart Failure. Circulation 2019; 139(5): 575–586.
Chen CI, Kao PF, Wu MY, et al. Influenza Vaccination is Associated with Lower Risk of Acute Coronary Syndrome in Elderly Patients with Chronic Kidney Disease. Medicine (Baltimore) 2016; 95(5): 2588.
Sung LC, Chen CI, Fang YA, et al. Influenza vaccination reduces hospitalization for acute coronary syndrome in elderly patients with chronic obstructive pulmonary disease: a population-based cohort study. Vaccine 2014; 32: 3843–3849.
Chlíbek R. Doporučená očkování seniorů. Remedia 2019.
Chlíbek R. Chřipka – očkovat, či neočkovat. TK SZÚ, 14. 10. 2019. Dostupné na: www.szu.cz.
Sheikh S, Biundo E, Courcier S, et al. A report on the status of vaccination in Europe. Vaccine 2018; 36 (33): 4979–4992.
Poscia A, Collamati A, Carfi A, et al. Influenza and pneumococcal vaccination in older adults living in nursing home: a survival analysis on the SHELTER study. Eur J Publ Health 2017; 27(6): 1016–1020.
Česká vakcinologická společnost ČLS JEP. Připravme se na zvýšený zájem o očkování proti chřipce. Publikováno 15. 5. 2020. Dostupné na: vakcinace.eu/novinky.
Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol 2020; 348: 103998.
van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65(1): 17–24.
Kozáková J. Surveillance pneumokokových onemocnění v ČR a vliv očkování na epidemiologii pneumokokových onemocnění. 15. Hradecké vakcinologické dny 2019. Dostupné na: vakcinace.eu/přednášky, staženo srpen 2021.
Kozáková J. Invazivní pneumokoková onemocnění v ČR v roce 2018. 15. Hradecké vakcinologické dny 2019. Dostupné na: vakcinace.eu/přednášky, staženo srpen 2021.
Kyaw MH, Rose CE Jr, Fry AM, et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005; 192(3): 377–386.
Kozáková J, Šebestová H, Křížová P. Invazivní pneumokokové onemocnění v ČR v roce 2015. Zprávy CEM. SZÚ, Praha 2016; 25(3): 100–107.
Shrestha S, Foxman B, Weinberger DM, et al. Identifying the interaction between influenza and pneumococcal pneumonia using incidence data. Sci Transl Med 2013; 5(191): 191ra84.
Dušek L, et al. Proočkovanost v dostupných datech národního zdravotnického informačního systému (NZIS). Prezentace HVD 2019. Dostupné na: www.vakcinace.eu.
Chlíbek R. Argumenty pro očkovat seniory proti pneumokokové infekci. Argumentační banka. Česká vakcinologická společnost.
Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205(9): 1408–1416.
Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372(12): 1114–1125.
Suaya JA, Jiang Q, Scott DA. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine 2018; 36(11): 1477–1483.
Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. Vaccine 2018; 36: 202–206.
Lee S, Bartlett B, Dwivedi G. Adaptive Immune Responses in Human Atherosclerosis. Int J Mol Sci 2020; 21(23): 9322.
Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68: 1069–1075.
Prymula R. Očkování proti pneumokokovým onemocněním a role replacementu. 15. Hradecké vakcinologické dny 2019.
Roubalová K, Seman J. Sérologický přehled protilátek proti herpetickým virům CMV, BV, VZV. Zprávy CEM 1998; 7(příloha 1): 29–31.
Burke BL, Steele RW, Beard OW, et al. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982; 142: 291–293.
Topinková E. Herpes zoster ve stáří a účinnost vakcinace v prevenci infekce virem herpes zoster a postherpetické neuralgie. Čes ger rev 2008; 6(1): 31–39.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271–2284.
Yawn BP, Wollan PC, Kurland MJ, et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011; 86: 88–93.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. N Engl J Med 2015; 372: 2087–2096.
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375: 1019–1032.
Fabiánová K, Zavadilová J, Šebestová H, et al. Syndrom dávivého kašle. Pertuse a parapertuse v České republice v roce 2017 – epidemiologická situace a přehled očkování proti pertusi. Zprávy CEM. SZÚ Praha 2018; 27: 75–83.
Chlibek R, Smetana J, Sosovickova R, et al. Seroepidemiology of whooping cough in the Czech Republic: estimates of incidence of infection in adults. Public Health 2017; 150: 77–83.
Fabiánová K. Pertuse – co je nového. 15. Hradecké vakcinologické dny 2019.
Halperin SA, Scheifele D, de Serres G, et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine 2012; 30: 974–982.